Hair Loss Treatment Online in California

Yes. California Business and Professions Code Section 2290.5 permits licensed physicians to prescribe appropriate medications via synchronous video telehealth without a prior in-person visit. TeleDirectMD's California-licensed board-certified Family Medicine physician evaluates your hair loss pattern, scalp photos or live video assessment, symptom history, and medical history before prescribing a physician-confirmed treatment regimen for androgenetic alopecia. This includes established therapies and off-label medications the physician has cross-checked. Self pay is $79; Aetna is in-network effective April 30, 2026.

TeleDirectMD prescribes finasteride 1 mg (FDA-approved for male AGA; off-label for post-menopausal women — physician-confirmed), dutasteride 0.5 mg (off-label for AGA — physician-confirmed superior DHT suppression), low-dose oral minoxidil (2.5–5 mg for men; 0.25–2.5 mg for women — off-label, physician-confirmed), and can recommend topical minoxidil 5% available over the counter. The physician assesses your specific pattern and medical history to determine the optimal regimen.

Finasteride 1 mg is FDA-approved for male androgenetic alopecia and has been in clinical use since 1997. AAD evidence shows 80–90% of men experience stabilization and 64% show measurable regrowth at 2 years. Side effects including sexual dysfunction (decreased libido, erectile dysfunction) occur in fewer than 2% of users and typically resolve with discontinuation. The physician discusses post-finasteride syndrome — a rare but documented persistent side effect — at treatment initiation. Finasteride is absolutely contraindicated in pregnant women due to risk of hypospadias in male fetuses.

Finasteride inhibits 5-alpha-reductase type 2 only, reducing scalp DHT by approximately 70%. Dutasteride inhibits both type 1 and type 2 (complete DHT suppression, reducing scalp DHT by approximately 90%). A 2023 Korean randomized controlled trial showed dutasteride 0.5 mg/day superior to finasteride 1 mg/day for hair density at 12 months. Dutasteride has a much longer half-life (approximately 5 weeks) — DHT suppression persists for weeks after stopping. Both are teratogenic — contraindicated in women who could become pregnant.

Low-dose oral minoxidil (2.5–5 mg for men; 0.25–2.5 mg for women) is an increasingly recognized off-label treatment for androgenetic alopecia, supported by multiple randomized controlled trials published in JAAD 2021–2023. At these low doses — far below the antihypertensive dose (10–40 mg/day) — oral minoxidil improves hair density with better adherence than topical application. The physician monitors blood pressure at initiation and screens for cardiac contraindications. Hypertrichosis (unwanted facial and body hair) is the most common side effect, dose-dependent and more common in women.

The physician assesses hair loss pattern during the video visit using: live scalp video assessment, review of scalp photos taken in natural light (front, vertex, and temporal views requested before the visit), description of hair loss duration and progression rate, family history, medication list (drug-induced alopecia), lab review (TSH, ferritin, CBC if available), and menstrual/hormonal history for women. The physician classifies the pattern as Norwood-Hamilton (male) or Ludwig (female) scale and determines whether treatment for androgenetic alopecia is appropriate or dermatology referral is needed.

Hair loss conditions requiring dermatologist evaluation: scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, discoid lupus — present with scalp inflammation and permanent follicle destruction), alopecia areata (patchy autoimmune hair loss — may respond to intralesional steroid injections or systemic immunotherapy), trichotillomania, secondary alopecia from systemic disease (lupus, iron deficiency anemia, thyroid disease — treat the underlying cause first), and sudden diffuse hair loss with systemic symptoms. TeleDirectMD will facilitate a referral when these conditions are suspected.

Yes. Female-pattern hair loss (FPHL) follows the Ludwig scale and affects approximately 25% of women by age 50. TeleDirectMD prescribes topical minoxidil 5% (off-label — physician-confirmed; FDA-approved is 2% for women), low-dose oral minoxidil (0.25–2.5 mg — off-label, physician-confirmed), finasteride 1 mg off-label for post-menopausal women (physician-confirmed; contraindicated in premenopausal women without reliable contraception), and may add spironolactone as an anti-androgen adjunct. The physician screens for hormonal causes (PCOS, post-menopausal androgen excess) before prescribing.

Generic hair loss medication costs with GoodRx coupons at California pharmacies (May 2026): generic finasteride 1 mg per month approximately $20–$40; generic dutasteride 0.5 mg per month approximately $25–$50; generic oral minoxidil 2.5 mg per month approximately $15–$40. Topical minoxidil 5% foam or solution (Rogaine/generic) is available over the counter for approximately $25–$40 per month without a prescription. Prescription costs are separate from the $79 TeleDirectMD visit fee.

Yes. California Business and Professions Code Section 2290.5 does not require a prior in-person visit for telehealth prescribing of non-controlled medications. Finasteride, dutasteride, and oral minoxidil are not controlled substances and can be prescribed via a California video visit. The Medical Board of California holds telehealth physicians to the same standard of care as in-person physicians — which TeleDirectMD satisfies through thorough pattern assessment, contraindication screening, and lab review where indicated.

At your first visit, the physician reviews: your hair loss pattern duration and rate of progression; family history of hair loss; current medications (particularly anabolic steroids, spironolactone, chemotherapy, thyroid medications, blood thinners — which can affect hair); recent major illness, surgery, or childbirth (telogen effluvium causes); nutritional habits; for women, menstrual cycle regularity and signs of hormonal imbalance. If recent TSH and ferritin labs are available, the physician reviews them. Based on this, the physician discusses the most appropriate treatment options and prescribes accordingly.

Timeline for hair loss treatment response: topical minoxidil — initial shedding common in first 2–4 weeks (normal), visible stabilization at 3–4 months, measurable regrowth at 6–12 months; finasteride — stabilization typically seen at 3–6 months, maximum regrowth at 12–24 months; oral minoxidil — similar to topical, with regrowth visible at 6–12 months. Treatment must be continued long-term — hair loss returns within months of stopping any treatment. Annual review visits confirm response and allow treatment adjustments. The $79 TeleDirectMD visit covers annual follow-up reviews.